Company intelligence / Profile preview
Endotis Pharma
Romainville, France
- Ownership
- Private
- Employees
- ~34
- Development stage
- Other
01
Overview
Endotis developed small-glyco molecule anticoagulants and heparan sulfate mimetics for thrombosis and oncology. Clinical candidates EP-42675 and EP-217609 (Factor Xa and Factor Xa/thrombin inhibitors) were discontinued after early clinical studies. The company’s business model focused on reaching proof-of-principle or Phase II for out-licensing, but no active programs remain.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Endotis Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endotis Pharma.